Lilly's Baricitinib Wins US FDA Panel Thumbs Up For One Of Two Doses

Despite concerns about small size of safety database, Arthritis Advisory Committee endorses 2 mg dose; panel recommends against approval of 4 mg dose due to stronger thrombosis signal in clinical trials, brushing back Lilly's attempt to position the higher dose as having a positive benefit-risk profile in patients with more refractory disease.

FDA Advisory Committee Feature image

A US FDA advisory committee handed Eli Lilly & Co. a mixed verdict on its rheumatoid arthritis drug Olumiant (baricitinib), endorsing a 2 mg dose but not a 4 mg version due to a thrombosis signal in clinical trials.

At an April 23 meeting, the Arthritis Advisory Committee voted 10-5 for approval of 2 mg baricitinib, a JAK1/2 inhibitor,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers